Hepion Pharma annual meeting: equity plan & say-on-pay fail; 3 directors face majority withhold votes

Hepion Pharmaceuticals, Inc.

Proposal 3 (2022 Omnibus Equity Incentive Plan) failed: 11.0M for, 20.1M against.
Proposal 5 (say-on-pay) failed: 9.2M for, 21.6M against.
Directors Gary Jacob, John Brancaccio, and Timothy Block each received more withhold votes than for votes.
Proposal 4 (authorized share increase) adjourned to July 22, 2022 due to insufficient votes.
Proposal 2 (ratify BDO USA as auditor) passed with 31.1M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.